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WELCOME
We are pleased to present the Lehigh Valley Health 
Network (LVHN) Cancer Program’s 2014 Statistical 
Report, featuring data about our cancer cases 
in 2013, as well as information about our cancer 
services. Cancer care programs offered by LVHN 
include prevention, detection, diagnosis, genetics, patient 
navigation, nutritional services, social and psychological 
support, rehabilitation, clinical trials, multidisciplinary 
and coordinated care, surgery, radiation, chemotherapy 
and hemophilia care.
AMONG OUR ACCOMPLISHMENTS
LVHN’s Cancer Program has achieved a three-year reac-
creditation with commendation 2014-2017 Silver Level, 
by the American College of of Surgeons Commission on 
Cancer (ACOS/CoC).
OUR CANCER PROGRAM’S BREAST  
HEALTH SERVICES HAS ACHIEVED
 Reaccreditation by the National Accreditation Program 
for Breast Centers (NAPBC), napbc-breast.org
 Designation as a Certified Quality Breast Center from 
National Quality Measures for Breast Cancer (NQMBC)
 Breast Center of Excellence designation from the 
American College of Radiology (ACR)
In February 2012, our department of radiation oncology 
received three-year full accreditation from the American 
College of Radiology/American Society for Therapeutic 
Radiation Oncology.
The LVHN Cancer Program also proudly participated 
in the National Cancer Institute’s (NCI) Community 
Cancer Centers Program (NCCCP). Only 21 cancer 
institutions nationwide hold this distinction, 2010-2014. 
We are also an affiliate of Moffitt Cancer Center, Tampa 
Fla., and The Wistar Institute of Anatomy and Biology, 
Philadelphia.
ABOUT THE COVER
The finality bell is a symbol of cancer  
survivorship and hope. Patients are  
encouraged to ring the finality bell to  
celebrate the completion of cancer treatment.
OUR MISSION
We ease our community’s 
cancer burden  
by preventing cancer,  
by finding cancer early,  
by providing comprehensive 
diagnostic, consultative, 
treatment, support and 
survivorship services,  
and by educating health  
care professionals and  
residents of the communities  
we serve about advances  
in cancer care.
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LVHN CANCER CASE INFORMATION
The LVHN Cancer Program offers a range of cancer services in convenient, patient-focused locations, including 
the John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital (LVH)–Cedar Crest, the Cancer Center 
at LVH–Muhlenberg, and the Health Center at Bangor. Patient care also is provided through Lehigh Valley Physician 
Group practice offices in Allentown, Bethlehem, Hazleton, Bangor and Lehighton.  Breast Health Services is offered in 
eight locations throughout the region.
The faculty of the Cancer Program is composed of physicians who are cancer care specialists and board-certified in 
their fields. In calendar year 2013, the Cancer Program saw more than 3,190 new cancer patients. Inpatient oncology ad-
missions were 3,529 in the fiscal year ending June 30, 2014, and outpatient volumes comprised of 3,718 unique patients 




















































































Cancer diagnosis, staging, incidence and treatment have a language of their own. Here are some commonly  
used terms and resources for more information:
American Joint Committee on Cancer (AJCC) staging: A classification system used for describing the extent of 
disease progression based on the evaluation of the tumor size/invasion (T), nodal status (N) and metastasis (M) at the 
time of diagnosis. AJCC staging is important in determining treatment plans.
Analytic cancer case: Analytic cases are cases for which the facility provided the initial diagnosis of cancer and/or for 
which the facility contributed to all or part of the first course of treatment.
Collaborative staging: Cancer stage historically has been collected using three different staging systems:  
AJCC (TNM), Surveillance, Epidemiology and End Results (SEER), Extent of Disease (EOD) and Summary Stage 
(SS). Collaborative staging is a unified data collection system designed to provide a common data set to meet the needs 
of all three staging systems and provide a comprehensive system to improve data quality by standardizing rules for 
timing, clinical and pathological assessments, and compatibility across all systems for all cancer sites.
National Cancer Database (NCDB): The NCDB is a joint project of the American Cancer Society and the 
Commission on Cancer. This database collects information on cancer cases diagnosed and/or treated at hospitals 
throughout the country. This non-patient-identified information is used to present scientifically reviewed descriptions 
of patient diagnosis, treatment and outcomes. The most recent data from NCDB is on cases newly diagnosed in 2012.
CANCER STAGING AND  
INCIDENCE TERMINOLOGY





















*Diagnosed and all first course of treatment 
received elsewhere prior to coming to 
Lehigh Valley Health Network.
NON-ANALYTICAL CASESTOTAL ANNUAL ANALYTIC CASES




















































BY COUNTY OF  
RESIDENCE
COUNTY OF RESIDENCE 2011 2012 2013
ADAMS 0 5 4
BEAVER 2 0 1
BERKS 166 196 213
BLAIR 0 0 1
BRADFORD 0 2 1
BUCKS 41 60 52
CARBON 168 191 185
CENTRE 0 0 0
CHESTER 3 4 2
CLINTON 0 0 0
CLEARFIELD 0 0 0
COLUMBIA 6 2 1
CUMBERLAND 1 1 0
DAUPHIN 0 2 1
DELAWARE 0 1 1
ELK 0 0 0
FAYETTE 0 0 0
FRANKLIN 0 0 0
LACKAWANNA 47 51 33
LANCASTER 1 1 1
LEBANON 2 1 2
LEHIGH 1,393 1,426 1,515
LUZERNE 73 77 97
LYCOMING 2 3 2
MONROE 127 124 122
MONTGOMERY 62 106 85
NORTHAMPTON 619 613 663
NORTHUMBERLAND 1 0 1
PERRY 0 0 0
PHILADELPHIA 0 0 5
PIKE 9 7 5
POTTER 1 0 0
SCHUYLKILL 120 130 121
SULLIVAN 0 0 0
SUSQUEHANNA 1 7 2
TIOGA 1 1 1
WARREN 1 0 0
WAYNE 6 15 5
WYOMING 1 3 1
YORK 3 1 1
OUT OF STATE 61 51 66
TOTAL 2,918 3,081 3,190
Lehigh Valley Health Network 
provides cancer care for patients 
in our community and serves as 
a tertiary referral center. In 2013 
alone, we provided diagnostic care, 
second opinion recommendations and 
treatment to more than 3,000 patients 
from 41 Pennsylvania counties. In 
addition, 66 patients came to our 
Cancer Program from communities 
across the United States.
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PRIMARY SITE TOTAL





COLON AND RECTUM 279
ANUS AND ANAL CANAL 21
LIVER AND BILE DUCTS 33
GALLBLADDER 5
OTHER BILIARY TRACT 8
PANCREAS 107
OTHER DIGESTIVE ORGANS 3
RESPIRATORY ORGANS 429
TRACHEA 1
BRONCHUS AND LUNG 418
THYMUS 2
HEART MEDIASTINUM PLEURA 8
MUSCULOSKELETAL SITES 31
BLOOD AND BONE MARROW 160
SKIN 172
BREAST 505





UTERUS (NOT OTHERWISE SPECIFIED-NOS) 9
OVARY 49
OTHER FEMALE GENITAL ORGANS 8
2013 ANALYTIC CASES BY  
PRIMARY BODY SITE
THIS CHART NOTES THE PRIMARY BODY SITE INVOLVED IN  
EACH PATIENT’S CANCER DIAGNOSIS.
PRIMARY SITE TOTAL




URINARY TRACT ORGANS 288
KIDNEY 124
KIDNEY, RENAL PELVIS 5
URETER 5
URINARY BLADDER 151
OTHER AND UNSPECIFIED URINARY ORGANS 3
CENTRAL NERVOUS SYSTEM 156
ENDOCRINE GLANDS 126
THYROID GLAND 110
OTHER ENDOCRINE GLANDS 16
OTHER 2
RETROPERITONEUM AND PERITONEUM 10
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PRIMARY BODY SITES: FIVE MOST FREQUENTLY TREATED AT LVHN
LUNG CANCER
INCIDENCE OF LUNG CANCER BY AGE AT DIAGNOSIS LVHN 2013
AGE AT DIAGNOSIS 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-100 TOTAL
(N) 1 2 14 64 128 140 65 4 418
LUNG CANCER TREATMENT BY STAGE AT DIAGNOSIS
FIRST COURSE Stage 1 Stage 2 Stage 3 Stage 4 Stage OC Stage UNK TOTAL
SURGERY ONLY 79 19 8 4 0 0 110
RADIATION ONLY 10 0 9 33 0 0 52
SURGERY AND CHEMOTHERAPY 3 7 6 2 1 0 19
RADIATION AND CHEMOTHERAPY 2 2 31 56 0 0 91
CHEMOTHERAPY ONLY 1 0 3 35 1 0 40
SURGERY, RADIATION AND CHEMOTHERAPY 0 3 9 1 0 0 13
OTHER SPECIFIED THERAPY 2 1 1 13 0 0 13
NO FIRST COURSE TREATMENT 6 1 15 43 4 7 76
TOTAL 103 33 82 187 6 7 418
INCIDENCE OF BREAST CANCER BY AGE AT DIAGNOSIS LVHN 2013
AGE AT DIAGNOSIS 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-100 TOTAL
(N) 0 18 82 141 130 80 48 6 505
BREAST CANCER TREATMENT BY STAGE AT DIAGNOSIS
FIRST COURSE Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Stage OC Stage UNK TOTAL
SURGERY ONLY 43 27 11 1 0 0 0 82
SURGERY AND RADIATION 22 29 5 0 0 0 0 56
SURGERY AND CHEMOTHERAPY 0 15 23 7 0 1 0 46
SURGERY, RADIATION AND CHEMOTHERAPY 0 18 14 10 1 0 0 43
SURGERY, RADATION AND HORMONE THERAPY 25 88 20 3 0 0 0 136
SURGERY AND HORMONE THERAPY 9 26 10 0 1 0 1 47
SURGERY, RADIATION, CHEMOTHERAPY AND 
HORMONE THERAPY 0 8 16 12 0 0 0 36
SURGERY, CHEMOTHERAPY AND  
HORMONE THERAPY 0 3 5 3 0 0 0 11
OTHER SPECIFIED THERAPY 1 1 3 5 19 0 1 30
NO FIRST COURSE TREATMENT 1 8 5 0 4 0 0 18
TOTAL 101 223 112 41 25 1 2 505
BREAST CANCER 1
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3INCIDENCE OF COLON CANCER BY AGE AT DIAGNOSIS LVHN 2013AGE AT DIAGNOSIS 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-100 TOTAL(N) 1 1 2 16 31 41 50 48 16 206COLON CANCER BY STAGE AT DIAGNOSISFIRST COURSE Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Stage UNK TOTALSURGERY ONLY 4 22 52 14 8 1 101
SURGERY AND CHEMOTHERAPY 0 0 6 33 18 0 57
CHEMOTHERAPY ONLY 0 0 0 0 11 0 11
SURGERY, RADIATION AND CHEMOTHERAPY 0 0 3 3 1 0 7
OTHER SPECIFIED THERAPY 0 0 1 5 1 1 1
NO FIRST COURSE TREATMENT 1 0 3 4 13 7 28
TOTAL 5 22 64 55 52 8 206
COLON AND RECTAL CANCER
INCIDENCE OF RECTAL CANCER BY AGE AT DIAGNOSIS LVHN 2013
AGE AT DIAGNOSIS 30-39 40-49 50-59 60-69 70-79 80-89 90-100 TOTAL
(N) 3 6 22 18 14 7 3 73
RECTAL CANCER TREATMENT BY STAGE AT DIAGNOSIS
FIRST COURSE Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Stage UNK TOTAL
SURGERY ONLY 1 14 2 0 1 3 21
SURGERY AND CHEMOTHERAPY 0 1 0 3 0 0 4
RADIATION AND CHEMOTHERAPY 0 0 2 2 4 0 8
CHEMOTHERAPY ONLY 0 0 0 0 1 0 1
SURGERY, RADIATION AND CHEMOTHERAPY 0 1 11 12 1 0 25
OTHER SPECIFIED THERAPY 1 0 3 0 1 1 6
NO FIRST COURSE TREATMENT 0 2 1 2 2 1 8
TOTAL 2 18 19 19 10 5 73
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43 INCIDENCE OF PROSTATE CANCER BY AGE AT DIAGNOSIS LVHN 2013AGE AT DIAGNOSIS 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-100 TOTAL(N) 0 0 4 52 97 35 14 3 205
INCIDENCE OF MELANOMA OF THE SKIN BY AGE AT DIAGNOSIS LVHN 2013
AGE AT DIAGNOSIS 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-100 TOTAL
(N) 3 6 19 36 40 34 22 1 161
PROSTATE CANCER TREATMENT BY STAGE AT DIAGNOSIS
FIRST COURSE Stage 1 Stage 2 Stage 3 Stage 4 Stage UNK TOTAL
SURGERY ONLY 11 63 9 0 1 84
RADIATION ONLY 9 13 0 1 0 23
SURGERY AND HORMONE THERAPY 1 34 1 7 0 43
SURGERY, RADIATION AND HORMONE THERAPY 1 1 3 1 0 6
SURGERY AND HORMONE 0 4 1 1 1 7
SURGERY AND RADIATION 1 0 6 0 0 7
HORMONE THERAPY ONLY 0 1 0 5 0 6
OTHER SPECIFIED THERAPY 0 1 0 0 0 1
NO FIRST COURSE TREATMENT 23 3 1 1 0 28
TOTAL 46 120 21 16 2 205
MELANOMA OF THE SKIN BY STAGE AT DIAGNOSIS
FIRST COURSE Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Stage UNK TOTAL
SURGERY ONLY 25 85 19 3 0 9 141
SURGERY AND IMMUNOTHERAPY 0 0 0 4 1 0 5
SURGERY, CHEMOTHERAPY AND OTHER 0 0 0 2 0 0 2
SURGER AND RADIATION 0 0 3 0 0 0 3
SURGERY, RADATION AND OTHER 0 0 1 0 1 0 2
SURGERY, CHEMOTHERAPY AND RADIATION 0 0 0 0 1 0 1
OTHER SPECIFIED THERAPY 0 0 1 1 2 0 4
NO TREATMENT 0 0 0 0 2 1 3
TOTAL 25 85 24 10 7 10 161
PROSTATE CANCER
MELANOMA
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CLINICAL TRIALS 
When you face a cancer diagnosis, clinical trials  
sometimes offer the best possibility for extending life 
expectancy. At Lehigh Valley Health Network, our  
clinical trials program is as robust as you will find 
anywhere in the U.S. 
 
Our success is a result of many factors:
  Our selection as a National Cancer Institute  
Community Cancer Centers Program–NCCCP  
(2010-2014)
  Partnerships with Moffitt Cancer Center  
in Tampa, Fla., and with The Wistar Institute in 
Philadelphia;
  Dedicated clinical trials staff that helps ensure  
we follow the strictest of clinical trial protocols and 
deliver clear results, while providing compassionate  
care for our patients.
OUR PROGRAM IS ABLE TO OFFER STUDIES 
THAT PROVIDE EARLY ACCESS TO TREAT-
MENTS AND THERAPIES:
Phase 2 – Study to measure the effectiveness of therapy;
available at limited number of centers
Phase 3 – Larger study to measure effectiveness
Having access to clinical trial medicines in a phase 2  
study provides the latest advancements in cancer care  
to our patients close to home.
SUCCESS AGAINST MELANOMA
LVHN is the only academic community hospital among 
eight major medical institutions selected to take part 
in five early-phase clinical trials conducted over the last 
year and a half involving immunotherapy and stage 4 
melanoma. One phase 2 trial tested the sequential use 
of two immunotherapy drugs: ipilimumab (Yervoy) and 
anti-PD-1 (Nivolumab), both of which boost the immune 
system’s response to melanoma cells.
Three out of the four LVHN patients who received 
treatment for the clinical trial are now one year out and 
in complete remission. With these three immunotherapy 
drugs – interleuken-2 (IL-2), ipilimumab and anti-PD-1 
– there is more hope than ever for long-term remissions 



















INNOVATIONS AND IMPACT 
Year after year, the Cancer Program at Lehigh Valley Health Network continues to grow. Not only have we 
experienced steady growth in the number of patients for whom we provide care, we also have become a leader in our area 
offering specialized procedures and treatments. Among our areas of specialization: clinical trials, robotic surgery, liver and 
pancreatic surgeries, (Whipple procedure), neuro-oncology specialization, thyroid surgery and stereotactic radiosurgery.
358
2014 Clinical trial participants
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At LVHN, our robotic surgery program features one of the nation’s largest teams skilled in  
using da Vinci® Si HD Surgical Systems. Each robotic system offers high-definition, 3-D views 
of the surgery site coupled with precise instrument control. Using this tool, our surgeons can 
perform complex and delicate surgeries, such as gynecologic and fertility-sparing surgery,  
urologic, thoracic, colon-rectal as well as other surgeries.
Robotic surgery usually involves three to five small incisions. For some conditions,  
Lehigh Valley Health Network now offers da Vinci® Single Site® Surgery, where the surgeon 
operates through a single small incision of less than 1 inch long.
 
BENEFITS OF ROBOTIC SURGERY MAY INCLUDE:
  Smaller incisions
  Less pain, scarring and recovery time
  Shorter hospital stay
  Lower risk for infection
  Less blood loss and fewer transfusions
  Quicker return to normal activities
4,000+
Procedures
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EXPERTISE IN PANCREATIC AND  
LIVER SURGERIES
Surgical techniques in pancreatic and liver surgeries at Lehigh Valley Health Network (LVHN) are improving 
outcomes for oncology patients. By using a precise, anatomic-based approach to these complex surgeries, LVHN’s 
surgical oncologist and hepatic and pancreatobiliary specialist have significantly reduced typical operating times.
At LVHN we performed more than 100 pancreatic and liver surgeries in 2014, well above the standard that mea-
sures “high volume” which is set at a minimum of 20 pancreatic resections and 20 liver resections annually. Studies 
suggest a correlation between improved patient outcomes and high-volume centers and high-volume surgeons.
PANCREATIC RESECTION












































TIME 2 hr. 42 min.
BLOOD TRANSFUSION 8%








WHAT IS HIGH VOLUME?
 Pancreatic resection  
a minimum of 20 per year
 Liver resection  
a minimum of 20 per year
 Indicates start of surgical oncologist at LVH
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NEURO-ONCOLOGY
When a person hears the words, “You have a brain tumor,” 
there is a rush of worry about the future and wondering, 
“What’s next?” The neuro-oncology team at Lehigh Valley 
Health Network is comprised of individuals who exemplify the 
definition of a “multidisciplinary team.” Each member of our 
neuro-oncology team – neurosurgeons, neuroradiologists, 
radiation oncologists and a neuro-oncologist – is focused on 
treating each patient with dignity and compassion during a 
difficult time, while also developing a treatment protocol that 
not only treats your brain tumor, but preserves healthy brain 
tissue and function for a better outcome.
HOW THE LVHN NEURO-ONCOLOGY  
TEAM CARES FOR YOU
Each patient’s treatment plan results from the recommenda-
tions of a multidisciplinary care team. Among the techniques 
the team may utilize:
  Gamma Knife® radiosurgery, performed with the newest-
generation Gamma Knife Perfexion™ technology. Lehigh 
Valley Hospital–Cedar Crest is the first hospital in the 
region to offer this model, which provides faster setup and 
treatment times, reduces radiation to unintended areas 
and offers enhanced ability to form complex treatment 
plans and care for a wider range of targets. 
  The latest research studies and research-based treatments. 
As the region’s only National Cancer Institute Community 
Cancer Centers Program (2010-2014), LVHN patients have 
access to limited-availability studies and trials.
SPECIALTY TEAM
  Four board-certified neurosurgeons, including two who are 
fellowship-trained in neuro-oncology
  The region’s only board-certified neuro-oncologist who 
participates in the team approach to patient care
  Ten specialty-trained neuroradiologists
  Two specialty-trained radiation oncologists specializing in 
the care of brain tumor patients
  A team of neurophysiologists dedicated to intraoperative 
monitoring










pathologist in the region
2 
Specialty-trained radiation 
oncologists specializing in the  
care of brain tumor patients
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RADIATION ONCOLOGY
Radiation therapy may play a crucial role in your cancer care. At Lehigh Valley Health Network, you have the 
security of knowing you are receiving care from experienced physicians, nurses, therapists and other professionals who are 
specialists in their fields and who have helped thousands of patients confront cancer.
Radiation oncology at the LVHN Cancer Center offers patients the availability of the finest state-of-the-art technology 
and techniques. Radiation oncology facilities at LVHN include:
 Linear accelerators (six)
 Stereotactic body radiotherapy (SBRT)
 Gamma Knife® radiosurgery
 Intensity-modulated radiation therapy (IMRT)
 CT simulators (two)
 Brachytherapy – high-dose and low dose
 3-D treatment planning
 Image-guided radiation therapy (IGRT)
 Respiratory gating
 RapidArc technology
OUR PROGRAM ALSO OFFERS THE LATEST IN TREATMENT  
PROTOCOLS AND TECHNOLOGIES, INCLUDING:
Metal artifact reduction software (MAR): LVHN is among a few select cancer centers in the United States – and the 
only hospital in northeastern Pennsylvania – offering a special type of CT scan, used for preparing radiation therapy 
treatments, that reduces the undesirable display of artifacts in the CT images produced by metal in the body. Metal arti-
facts are caused by objects like dental fillings, joint replacement implants, screws, metal plates or pins that are commonly 
used for back, spinal or bone procedures.
When you have a traditional CT scan, which is a type of X-ray, metal artifacts can appear as white and black streaks 
on the image. These streaks may obscure part of your internal anatomy, making it more challenging to develop the radia-
tion treatment plan. However, at LVHN, if you have metal objects in the area to be treated, you can have your simulation 
CT scans performed with the GE Optima580RT CT scanner. This device features revolutionary software that reduces the 
streaks created by metal objects and helps ensure treatment plans are made with the best visualization possible.
Prone breast radiation therapy: Prone breast radiation therapy is performed with the patient lying face down on a 
special table, which allows the breast to fall away from the chest wall. This positioning reduces the radiation doses to the 
heart and lungs, and is especially helpful for women with large breasts.
Pediatric radiation oncology: Children and adolescents with a malignancy have a unique set of needs. For patients  
requiring radiation therapy The Children’s Hospital at Lehigh Valley Hospital offers benefits specific to pediatric patients, 
beginning with our full-time physicists and dosimetrists who develop custom radiation treatment plans for children.
Our professional staff also ensures patients and their families understand the child’s treatment. We follow a structured, 
child-friendly education program (using iPad®s and even crafts) to orient patients and parents to radiation oncology tech-
nology and treatment. The child-friendly experience extends to the children’s area of the radiation oncology department 
where walls are decorated with a mural created by the Baum School of Art, Allentown.
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INFUSION SERVICES
Patients who require intravenous (IV) therapy for oncology  
or non-oncology disorders may receive their care at one  
of our three convenient and comfortable infusion locations:
 Health Center at Bangor infusion services
  Multipurpose area infusion services at the John and Dorothy  
Morgan Cancer Center at Lehigh Valley Hospital (LVH)–Cedar Crest
  Multipurpose-satellite infusion services at  
Lehigh Valley Hospital–Muhlenberg
Health Center at Bangor: 12 infusion bays
LVH–Cedar Crest: 38 infusion bays
LVH–Muhlenberg: 24 infusion bays
BREAST HEALTH SERVICES (BHS)
Breast Health Services of Lehigh Valley Health Network offers women a caring environment for breast screening 
and diagnostic studies provided by staff members who excel in their profession. Among our designations:
 Accredited by the National Accreditation Program for Breast Centers (NAPBC)
 Designated Breast Center of Excellence by the American College of Radiology (ACR)
 “Certified Quality Breast Center” by the National Quality Measures for Breast Centers (NQMBC)
32,712 




3-D Tomosynthesis exams in 2013
3-D DIGITAL TOMOSYNTHESIS
Women with dense breast tissue may wish to have a mammogram done  
using 3-D digital tomosynthesis. This technology provides clear, 3-D images  
of breast tissue by showing results in very thin cross-section images. 
  Provides improved view enabling doctors to more effectively  
pinpoint any abnormalities.
  Reduces the false positive rate of screening mammograms. Study results  
at LVHN: Use of 3-D tomosynthesis reduced the recall rate for further  
screening by 36 percent (presented at 24th National Consortium of Breast 
Centers Conference, March 15-19, 2014, Las Vegas).
 Allows very small cancers to be seen at an earlier stage.
BHS at LVH–Muhlenberg was the first in the region to offer this technology 
in September 2012. We now offer 3-D tomosynthesis at three BHS loca-
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TUMOR REGISTRY
To help us zero in on cancer and its characteristics, LVHN 
tracks important data about patient tumors leading to an 
understanding of how cancer presents, how it is treated 
and the outcomes of therapy in our patient population. 
The Cancer Data Management department captures a complete 
summary of patient history, diagnosis, treatment and status 
for every cancer patient seen at LVHN. The data is used to 
evaluate patient outcome, quality of life, calculate survival rates, 
report cancer incidence as required by the PA Cancer Registry 
and the National Cancer Database, and evaluate effectiveness 
of treatment modalities in an effort to improve the quality of 
care we deliver. As part our commitment to long-term care and 
education, we offer lifetime patient follow-up to gather data that 
benefits our patients now and into the future.
MULTIDISCIPLINARY CLINICS (MDC)
When you are faced with a cancer diagnosis, it is important to understand your options. At Lehigh Valley Health 
Network, we offer a multidisciplinary team approach to your care. This means you will have access to doctors and support 
staff that understand the facets of your condition and can provide you with the information you need to make important 
decisions. An MDC coordinates all of your oncology team members through one appointment and can be used as a primary 
appointment for treatment discussions or as a second opinion service. A nurse navigator will coordinate your appointment 
and stay with you through treatment completion.





Patient cases were reviewed at a  
multidisciplinary Tumor Board in 2013
1,285 
Patients were seen in  
MDC clinics in fiscal year 2014
13 SITE-SPECIFIC  
TUMOR BOARDS
 1  Adolescent and young adult
 2  Breast
 3  Colon-rectal
 4  Combined tumor board
 5  Ear nose throat
 6  Endocrine
 7  Gynecology
 8  Hepatobiliary
 9   LVH–Muhlenberg general tumor board
10  Neurology
11  Pulmonary
12  Skin and soft tissue
13  Urology
TUMOR BOARD MEMBERS
  Medical oncologist
  Surgical oncologist
  Diagnostic radiologist
  Pathologist
  Radiation oncologist
  Genetic counselor
  Support counselor
  Palliative care provider
  Nurse navigator
 Tumor Registrar and many more
30,096 
Patients followed for life
  Prostate
  Survivor PLACE
  Thoracic
VISIT LVHN.ORG     CALL 610-402-CARE  17
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COUNSELING SERVICES
A cancer diagnosis can create strong feelings of grief, sadness, 
anger or fear. Our licensed counselors with an expertise in 
cancer care are available to support patients, their families and 
caregivers cope with the diagnosis in an effort to help feel less 
distressed. Counselors can make visits to the doctor’s office or 
treatment area. They are also available by appointment.
FINALITY BELL
The finality bell is a symbol of cancer survivorship and a 
source of hope. LVHN has three, donated by patients, so  
fellow survivors can ring the bell as a way to celebrate their 
final day of cancer treatment. 
 
CANCER RISK AND GENETIC ASSESSMENT
While most cancers are not inherited, family and personal 
medical histories are important to identify people at higher 
risk for certain cancers. 
Three board-certified genetic counselors and a medical  
oncologist are available to meet with patients and families  
to discuss benefits of genetic testing and perform a  
personalized cancer risk assessment. The genetic counselors 
provide an in-depth review of results, counsel patients and 
family members on implications, and provide comprehen-
sive treatment and surveillance recommendations.
FINANCIAL COORDINATION
The LVHN Cancer Program provides five financial co-
ordinators to assist patients in reducing financial barriers 
to care. They answer questions related to precertification 
requirements, health insurance and medical bills. Financial 
coordinators also connect patients with support agencies 
to assist them in receiving free or reduced-cost services and 
medical supplies if they qualify.
  Financial coordinators assisted 152 patients in obtaining 
$3.3 million dollars in free or reduced-cost oral medica-
tions in fiscal year 2014.
NURSE NAVIGATION
Nurse navigators follow patients from diagnosis through 
treatment completion. This specialized care team member 
offers each patient emotional support, helps the patient 
communicate with his or her physicians, and provides 
guidance for decision-making about his or her care. Navi-
gators direct patients to support services and community 
resources to assist them with treatment-related supplies, fi-
nancial concerns and transportation. They serve as a single 
point of access and help coordinate all members of the 
patient’s health care team. When treatment is complete, 
the navigator guides the patients to survivorship services as 
appropriate. At LVHN, we have six nurse navigators, two 
of whom are bilingual in Spanish to help meet the cultural 
needs of our patients.
NUTRITION COUNSELING
Three oncology-certified registered dietitians are available 
to meet with patients and families to assess nutritional 
needs and determine appropriate nutritional goals and 
strategies during treatment as well as during survivorship.
  Our dietitians provided 2,050 visits in fiscal year 2014.
CANCER SUPPORT SERVICES
478 
New genetics patients  
counseled in fiscal year 2014
500% 
Increase in referrals to  
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PALLIATIVE CARE
Managing one complex illness such as congestive heart failure 
(CHF) is difficult. If you have two or more complex illnesses,
such as CHF and cancer, then additional medical assistance is
often needed. That’s where palliative care can help. The word 
“palliate” means to comfort, and at LVHN a team called OACIS 
(optimizing advanced complex illness support) provides comfort 
and care. The OACIS team includes doctors, nurse practitioners, 
social workers, clergy and community groups. 
How it’s different from hospice care – Hospice care provides 
services for people at the end of life. Palliative care is for anyone 
facing one or more serious illnesses, at any stage of illness. That 
said, if you are facing a terminal illness, OACIS can assist  
you with completing advance directives and will work closely  
with hospice as needed. We also can help you through the  
difficult decision on whether to focus on curing your illness or 
managing your pain and symptoms.
How to access OACIS – Ask your doctor for a palliative  
medicine consultation so he or she can refer you to receive 
OACIS care.
  In your home through our home-based consult service
  As a patient in one of LVHN’s hospitals
  By making an appointment at the OACIS outpatient clinic
CANCER REHABILITATION
If you are suffering from fatigue, weakness, balance problems, 
lymphedema or other symptoms related to your condition  
and treatment, our trained rehabilitation therapists can help 






Lehigh Valley Health Network works 
with community organizations such 
as the American Cancer Society, 
Lymphoma & Leukemia Society, 
the Mark J. Young, MD, Community 
Health and Wellness Center, the 
Allentown Health Bureau and 
other community representatives 
to accomplish outreach activities. 
Prevention, along with early detection 
and screening programs, are offered to 
residents of our area utilizing nationally 
accepted evidence-based guidelines and 
interventions.
FREE CANCER SCREENINGS
  Breast: 737 mammograms
  Cervical: 735 Pap tests
  Skin: 105 skin exams
  Oral: 31 oral exams
2014 EDUCATION AND 
PREVENTION WORKSHOPS 
  Nutritional Education Series
  Kinnon Breast Cancer Survivor 
workshop
  Latino Cancer Survivor  
Education Series
  The Legacy Program for Cancer 
Survivors
  Survivor Celebration and Robotic 
Olympics
  LVHN Health Fair Night at  
Coca-Cola Park
  Catch Them Early – Importance  
of Skin Cancer Detection








20   LEHIGH VALLEY HEALTH NETWORK
OUR AWARDS, CERTIFICATIONS  
AND ACCREDITATIONS
NATIONAL ACCREDITATION PROGRAM FOR 
BREAST CENTERS (NAPBC)
Lehigh Valley Health Network’s Breast Health 
Services is accredited by the National Accredita-
tion Program for Breast Centers (NAPBC). 
COEMIG™ DESIGNATION
Eight of our doctors also have earned  
COEMIG™ designation from the AAGL 
(American Association of Gynecologic  
Laparoscopists), whose mission is advancing minimally 
invasive gynecology worldwide. 
ACR AND THE AMERICAN SOCIETY FOR 
RADIATION ONCOLOGY (ASTRO) SEAL OF 
ACCREDITATION
Lehigh Valley Hospital–Cedar Crest and Lehigh 
Valley Hospital–Muhlenberg have been awarded 
the ACR and the American Society for Radia-
tion Oncology (ASTRO) seal of accreditation. 
AMERICAN COLLEGE OF RADIOLOGY (ACR) 
FOR BREAST MAMMOGRAPHY
Lehigh Valley Health Network has earned 
accreditation from the American College of 
Radiology (ACR) for breast mammography. 
BREAST IMAGING CENTER OF EXCELLENCE
LVHN Breast Health Services is also designated 
as a Breast Imaging Center of Excellence by the 
ACR. 
U.S. NEWS & WORLD REPORT 
Each year, U.S. News & World Report ranks 
hospitals according to patient satisfaction, 
patient outcome and access to leading-edge 
care across many specialties. In cancer care, 
U.S. News & World Report recognizes Lehigh Valley 
Hospital as “high performing” in recognition of our 
qualified staff, patient access to advanced technologies 
and patient survival.
BLUE DISTINCTION CENTER FOR COMPLEX 
AND RARE CANCERS
Highmark Blue Shield  has named Lehigh 
Valley Hospital–Cedar Crest as a Blue Distinc-
tion Center for Complex and Rare Cancers, focusing on 
complex inpatient and surgical care. 
COMMISSION ON CANCER
Continuously since 2005, Lehigh Valley 
Health Network has been an accredited 
cancer program through the American 
College of Surgeons Commission on Cancer® (CoC), a des-
ignation only granted when a facility voluntarily commits to 
provide the best in cancer diagnosis and treatment, while also 
complying with standards established by the CoC.
AMERICAN SOCIETY OF CLINICAL  
ONCOLOGY (ASCO) QOPI® CERTIFICATION 
PROGRAM (QCP™)
Hematology-Oncology Associates of 
Allentown, Bethlehem and Bangor, 
a practice of Lehigh Valley Physician 
Group, actively participates in the American Society of 
Clinical Oncology (ASCO) QOPI® Certification Program 
(QCP™) and has been continuously certified since 2011. 
NATIONAL COMMITTEE FOR QUALITY  
ASSURANCE (NCQA)
Hematology-Oncology Associates (HOA) at 
Lehigh Valley Hospital–Cedar Crest and Lehigh 
Valley Hospital–Muhlenberg has been recog-
nized by the National Committee for Quality Assurance 
(NCQA) for three years. 
NATIONAL CANCER INSTITUTE’S  
COMMUNITY CANCER CENTERS  
PROGRAM (NCCCP) 
Lehigh Valley Health Network’s Cancer Center 
was one of 21 sites in the United States selected 
to be part of the National Cancer Institute’s 
Community Cancer Centers Program (NCCCP) (April 
2010 to June 2014).
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Patient and tumor characteristics and BRAF and KRAS 
mutations in colon cancer, NCCTG (Alliance N0147). Gonsalves, 
WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, 
Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, 
Chan E, Nair S, Berenberg JL, McWilliams RR 
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PMID 24925349
KRAS Codon 12 and 13 mutations in relation to disease-free 
survival in BRAF wild type stage III colon cancer from an 
adjuvant chemotherapy trial (N0147 Alliance). Yoon HH, Tougera 
D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau 
SN, Goldberg RM, Sargent DJ, Sinicrope FA: Alliance for Clinical Trials 
in Oncology. Clinical Cancer Research: 2014 Jun 1: 20(11): 3033-43. 
PMID 24687927
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intergroup trial N0147. Huang J, Nair SG, Mahoney MR, Nelson GD, 
Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry 
JT, thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Welb TA,  
Farr GH, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR;  
Clinical Colorectal Cancer. 2014 Jun 13 (2): 100-9.  PMID 24512953
Hypoxia induces phenotypic plasticity and and therapy 
resistance in melanoma via the tyrosine kinase receptors  
ROR1 and ROR2. O’Connell MP, Marchbank K, Webster MR, Valiga 
AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, 
Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA,  
Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, 
Karakousis GC, Xu W, Xu X, Weeraratna AT.  
Cancer Discovery 2013 Dec;3(12):1378-93. PMID 24104062
Plasmablastic lymphoma of the maxillary sinus in an HIV-
negative patient: a case report and literature review.  
Saraceni C, Agostino N, Cornfield DB, Gupta R. 
Springerplus. 2013 Apr 3;2(1):142. Print 2013 Dec. PMID:23667804
Pneumococcal sepsis-induced purpura fulminans in an 
asplenic adult patient without disseminated intravascular 
coagulation. Saraceni C, Schwed-Lustgarten D 
American Journal of the Medical Sciences. 2013 Dec;346(6):514-6. 
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Cystic Brain Metastases in NSCLC harboring the EML4-ALK 
Translocation after Treatment with Crizotinib.  
Christine Saraceni, DO, P. Mark Li, MD, Justin F Gainor, MD, Gary 
A. Stopyra, MD and Eliot L. Friedman, MD. Accepted by Journal of 
Thoracic Oncology. 
A prospective evaluation of vascular endothelial growth factor 
(VEGF) and the immune system in stage III/IV melanoma.   
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Annual Conference Academy of Oncology Nurse Navigators, November 
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CONTACT US
If you have a question about Lehigh Valley 
Health Network services or the Cancer 
Program, please call 610-402-CARE.
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OUR LOCATIONS 
THE LVHN CANCER PROGRAM OFFERS A RANGE OF SERVICES IN CONVENIENT,  
PATIENT-FOCUSED LOCATIONS.
Allentown – John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital (LVH)–Cedar Crest
Bethlehem – Cancer Center at Lehigh Valley Hospital–Muhlenberg
Bangor – Health Center at Bangor 
We also provide patient care at Lehigh Valley Physician Group practice offices in Allentown, Bangor, 
Bethlehem, Hazleton and Lehighton.
BREAST HEALTH SERVICE LOCATIONS
Breast Health Services – 17th Street, Allentown
Breast Health Services – LVH–Cedar Crest
Breast Health Services – LVH–Muhlenberg
Health Center at Bangor
Health Center at Bath
Health Center at Bethlehem Township
Health Center at Moselem Springs
Health Center at Trexlertown
OVERNIGHT ACCOMMODATION FOR PATIENTS AND GUESTS
The Hackerman-Patz House at Lehigh Valley Hopsital–Cedar Crest is a convenient and affordable alterna-
tive to an expensive hotel or daily trips to and from a distant home. Whether you are receiving care here, or 
your loved one is a patient at our hospital, the Hackerman-Patz House offers you comfortable accommo-
dations and a supportive environment that allows you to focus on healing. Financial assistance is available.
Reserve your room at the Hackerman-Patz House. Call 610-402-9500 or visit LVHN.org/familylodge.

